Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rani Shares Positive Oral Ustekinumab Data After Last Year’s Challenges

RT-111 Oral Ustekinumab Biosimilar Passes Phase I Trial After Company Prioritization

Executive Summary

Rani Therapeutics announced positive topline results from a Phase I trial of its oral Stelara biosimilar, moving it further in a crowded market with fierce competition.

You may also be interested in...



Alvotech Lines Up US Biosimilar Approvals After FDA Inspection

Alvotech has revealed details of exactly when it expects to win US FDA approvals for its Teva-partnered Humira and Stelara biosimilars, after an agency reinspection of its manufacturing plant in Reykjavik, Iceland resulted in just a single “readily addressable” Form 483 observation.

Stada And Alvotech Eye Launch Date For Ustekinumab After EU Approval

Stada has revealed details of exactly when in 2024 it plans to launch its Alvotech-partnered Uzpruvo ustekinumab biosimilar to Stelara, having just been granted a pan-European marketing authorization. At the same time, the German firm has also struck a distribution deal for prescription and consumer healthcare products with Zuellig in the Philippines.

Trailblazer Amgen Scoops First US Stelara Biosimilar – With Interchangeability

With its portfolio of biosimilars continuing to grow, Amgen has received the first approval in the US for a biosimilar to Stelara – weeks after Alvotech/Teva was hit with a complete response letter.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153272

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel